Neutral Lipid Delivery Technology Platform
Development of antisense drugs has been limited by the lack of a suitable method to deliver high concentration of these drugs to the diseased cells.
Bio-Path's delivery technology is different from most other lipid-based delivery technologies, which use positively charged lipids to form complexes between the lipids and the molecules of interest. Bio-Path's neutral lipids form structures similar to the cellular membrane, therefore allowing the antisense drug to be incorporated within the lipid layers and be delivered to the diseased cells with high uptake into the cell.
The major benefit of Bio-Path's neutral lipid technology compared to the cationic lipid technology is that there has been no evidence of toxicity with Bio-Path's technology, while cationic lipid technology has known toxic side effects that have limited its development into viable treatments for cancer.
Bio-Path’s neutral lipid delivery technology provides systemic distribution of nucleic acid antisense drugs throughout the human body by simple intravenous infusion.
Bio-Path seeks to apply its proprietary technology to new protein targets in cancer and in other disease indications. The Company is interested in pursuing a wide-ranging, proactive licensing program to include co-development of a specific liposomal antisense drug candidate; sub-license the delivery template for outside development of one or more liposomal antisense drug candidates; or out-license a partially developed drug for final development and marketing.
- Pipeline Status: Preclinical
- Platform: Platform Technology
- Published Date: 30 Sep 2015
- Original Date: 30 Sep 2015
- Contact Person: Peter Nielsen
- Bio-Path Holdings
- United States
- Telephone: 832-742-1357
- Web URL: http://www.biopathholdings.com/
- Therapeutic Areas:
- Drug Delivery
- Technical Applications